Loomis, Sayles & Company
AMED

Loomis, Sayles & Company’s Amedisys AMED Stock Holding History

Loomis, Sayles & Company’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19
Closed -$3K – 968
2022
Q1 		$3K Buy
+19
New +$2.84K ﹤0.01% 838
2021
Q4 		– Sell
-48
Closed -$7K – 770
2021
Q3 		$7K Buy
+48
New +$9.98K ﹤0.01% 875
2021
Q2 		– Sell
-97,429
Closed -$25.8M – 832
2021
Q1 		$25.8M Sell
97,429
-150,121
-61% -$42.3M 0.03% 255
2020
Q4 		$72.6M Sell
247,550
-1,547
-0.6% -$397K 0.1% 88
2020
Q3 		$58.9M Buy
249,097
+4,697
+2% +$1.07M 0.09% 90
2020
Q2 		$48.5M Buy
244,400
+21,076
+9% +$3.93M 0.08% 98
2020
Q1 		$41M Sell
223,324
-33,664
-13% -$5.99M 0.08% 88
2019
Q4 		$42.9M Sell
256,988
-826
-0.3% -$123K 0.07% 107
2019
Q3 		$33.8M Buy
257,814
+29,241
+13% +$3.81M 0.07% 125
2019
Q2 		$27.8M Buy
228,573
+11,144
+5% +$1.32M 0.05% 159
2019
Q1 		$26.8M Sell
217,429
-11,745
-5% -$1.47M 0.05% 153
2018
Q4 		$26.8M Buy
229,174
+27,576
+14% +$3.25M 0.06% 132
2018
Q3 		$25.2M Sell
201,598
-65,838
-25% -$7.27M 0.05% 184
2018
Q2 		$22.9M Buy
267,436
+3,999
+2% +$294K 0.05% 220
2018
Q1 		$15.9M Buy
+263,437
New +$15M 0.03% 310
2017
Q3 		– Sell
-118
Closed -$7K – 916
2017
Q2 		$7K Hold
118
– – ﹤0.01% 828
2017
Q1 		$6K Hold
118
– – ﹤0.01% 849
2016
Q4 		$5K Buy
+118
New +$5.02K ﹤0.01% 901

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Loomis, Sayles & Company's AMED Position: Q2 2022 in Review

Loomis, Sayles & Company sold out of Amedisys (AMED) in Q2 2022, closing a stake of 19 shares — an estimated $3K sold.

Loomis, Sayles & Company first reported a position in AMED in Q4 2016 and held it in 18 quarters. The position peaked at $72.6M in Q4 2020. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

  • Loomis, Sayles & Company reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 19 Amedisys shares in Q2 2022, an estimated $3K.
  • Loomis, Sayles & Company first reported a position in Amedisys in Q4 2016 and held it in 18 quarters.
  • Loomis, Sayles & Company's Amedisys position peaked at $72.6M in Q4 2020.
  • 288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Loomis, Sayles & Company's 13F filing for Q2 2022, filed 5 Aug 2022.